A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.

ABSTRACT:

Objective

We tested whether it is possible to differentiate relapsing-remitting (RR) from secondary progressive (SP) disease stages in patients with multiple sclerosis (MS) using a combination of nuclear magnetic resonance (NMR) metabolomics and partial least squares discriminant analysis (PLS-DA) of biofluids, which makes no assumptions on the underlying mechanisms of disease.

Methods

Serum samples were obtained from patients with primary progressive MS (PPMS), SPMS, and RRMS; patients with other neurodegenerative conditions; and age-matched controls. Samples were analyzed by NMR and PLS-DA models were derived to separate disease groups.

Results

The PLS-DA models for serum samples from patients with MS enabled reliable differentiation between RRMS and SPMS. This appr

SUBMITTER: Dickens AM 

PROVIDER: S-EPMC4222850 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature